- Nachrichtendetail
-
16.04.2024 13:04:29 - dpa-AFX: *ASTRAZENECA SAYS IMFINZI+CHEMOTHERAPY DOUBLED OVERALL SURVIVAL RATE AT THREE YEARS IN TOPAZ-1 PHASE III TRIAL
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
ASTRAZENECA PLC DL-,25 | 886455 | Frankfurt | 142,550 | 30.04.24 14:26:58 | +1,050 | +0,74% | 0,000 | 0,000 | 140,750 | 141,500 |
